Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joon Shin

Showing results (771-780 of 786) with videos related to

Pageof 79
Sort By:
Kidney Research and Clinical Practice|July 8, 2026
Efficacy, safety, and dose selection of efepoetin alfa in anemic patients on maintenance dialysis: a phase 2, randomized, multicenter, active-controlled trialEun Jeong Ko, Mi-Sun Byun, Chul Woo Yang, et al.
Cancer Chemotherapy and Pharmacology|January 15, 2013
Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancerKyung-Hun Lee, Hye Jung Chang, Sae-Won Han, et al.
Physics in Medicine and Biology|March 3, 2006
Compact soft x-ray transmission microscopy with sub-50 nm spatial resolutionKyong Woo Kim, Youngman Kwon, Ki-Yong Nam, et al.
Cell Reports. Medicine|September 17, 2025
Tumor-specific but immunosuppressive CD39<sup>+</sup>CD8<sup>+</sup> T cells exhibit double-faceted roles in clear cell renal cell carcinomaYong Joon Lee, Seung Hyuck Jeon, Jin Hee Yeo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2022
Oxaliplatin (3 months <i>v</i> 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07Seung Tae Kim, Sun Young Kim, Jeeyun Lee, et al.
Science Immunology|November 10, 2019
VEGF-A drives TOX-dependent T cell exhaustion in anti-PD-1-resistant microsatellite stable colorectal cancersChang Gon Kim, Mi Jang, Youngun Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2023
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket StudyYoshiaki Nakamura, Nobumasa Mizuno, Yu Sunakawa, et al.
International Journal of Medical Sciences|September 21, 2016
Overhydration Negatively Affects Quality of Life in Peritoneal Dialysis Patients: Evidence from a Prospective Observational StudyHye Eun Yoon, Young Joo Kwon, Ho Cheol Song, et al.
The Korean Journal of Internal Medicine|February 9, 2021
2020 Korean guidelines for the management of metastatic prostate cancerIn-Ho Kim, Sang Joon Shin, Byung Woog Kang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 23, 2022
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced MelanomaJason A Chesney, Antoni Ribas, Georgina V Long, et al.
Pageof 79

Showing results (771-780 of 786) with videos related to

Sort By:
Pageof 79
Kidney Research and Clinical Practice|July 8, 2026
Efficacy, safety, and dose selection of efepoetin alfa in anemic patients on maintenance dialysis: a phase 2, randomized, multicenter, active-controlled trialEun Jeong Ko, Mi-Sun Byun, Chul Woo Yang, et al.
Cancer Chemotherapy and Pharmacology|January 15, 2013
Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancerKyung-Hun Lee, Hye Jung Chang, Sae-Won Han, et al.
Physics in Medicine and Biology|March 3, 2006
Compact soft x-ray transmission microscopy with sub-50 nm spatial resolutionKyong Woo Kim, Youngman Kwon, Ki-Yong Nam, et al.
Cell Reports. Medicine|September 17, 2025
Tumor-specific but immunosuppressive CD39<sup>+</sup>CD8<sup>+</sup> T cells exhibit double-faceted roles in clear cell renal cell carcinomaYong Joon Lee, Seung Hyuck Jeon, Jin Hee Yeo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2022
Oxaliplatin (3 months <i>v</i> 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07Seung Tae Kim, Sun Young Kim, Jeeyun Lee, et al.
Science Immunology|November 10, 2019
VEGF-A drives TOX-dependent T cell exhaustion in anti-PD-1-resistant microsatellite stable colorectal cancersChang Gon Kim, Mi Jang, Youngun Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2023
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket StudyYoshiaki Nakamura, Nobumasa Mizuno, Yu Sunakawa, et al.
International Journal of Medical Sciences|September 21, 2016
Overhydration Negatively Affects Quality of Life in Peritoneal Dialysis Patients: Evidence from a Prospective Observational StudyHye Eun Yoon, Young Joo Kwon, Ho Cheol Song, et al.
The Korean Journal of Internal Medicine|February 9, 2021
2020 Korean guidelines for the management of metastatic prostate cancerIn-Ho Kim, Sang Joon Shin, Byung Woog Kang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 23, 2022
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced MelanomaJason A Chesney, Antoni Ribas, Georgina V Long, et al.
Pageof 79